Study on the antiviral activity of San Huang Yi Gan Capsule against hepatitis B virus with seropharmacological method

BMC Complementary and Alternative Medicine

Lijuan Zhou²  Cheng Peng³  Qinghe Wu¹  Haibo Xu³ 

[1] Department of Pharmacology, College of Pharmacy, Guangzhou University of Chinese Medicine, Guangzhou, China;Institute for Chinese Medicine Research, Sichuan Academy of Chinese Medicine Sciences, Chengdu, China;Department of Pharmacology, College of Pharmacy, Chengdu University of Traditional Chinese Medicine, 1166 Liutai Avenue, Wenjiang, Chengdu, Sichuan, P.R. China 611137

关键词: Seropharmacology;    San Huang Yi Gan capsule;    Hepatitis B virus;    Entecavir;   

Others  :  1220981
DOI  :  10.1186/1472-6882-13-239

 received in 2012-07-10, accepted in 2013-09-24,  发布年份 2013

【 摘 要 】

Background

Seropharmacology arising recently is a novel method of in vitro pharmacological study on Chinese herb using drug-containing animal serum. As seropharmacology possesses the advantages of experiments in vitro and in vivo, it is increasingly applied in pharmacological research on Chinese medicine. However, some issues of seropharmacology remain controversial and need to be clearly defined. San Huang Yi Gan Capsule (SHYGC) is a Chinese herbal formula with antiviral property against hepatitis B virus (HBV), but little is known about the mechanism underlying its anti-HBV activity. The aim of the present study was to elucidate the action mechanism of SHYGC using seropharmacological method and systematically address the methodology of preparing drug-containing serum.

Methods

New Zealand rabbits were orally administrated SHYGC with various regimens, followed by preparation of SHYGC-containing rabbit sera with a variety of methods. After HBV-producing HepG2 2.2.15 cells were treated with SHYGC-containing sera or entecavir for 9 days, the levels of hepatitis B surface antigen (HBsAg) and HBV DNA and the activity of DNA Polymerase were determined in HepG2 2.2.15 cells-conditioned media.

Results

An optimally standardized method of preparing drug-containing serum was raised for seropharmacology, with which SHYGC was demonstrated to suppress HBsAg expression, HBV DNA replication and DNA Polymerase activity in a dose-dependent fashion.

Conclusions

This seropharmacological study shows SHYGC is a potentially powerful anti-HBV agent. Additionally, seropharmacology is a promising pharmacological method with a broad range of advantages, and it can be widely used in biomedical research, if combined with pharmacokinetics.

【 授权许可】

   
2013 Xu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Bochu W, Liancai Z, Qi C: Primary study on the application of Serum Pharmacology in Chinese traditional medicine. Colloids Surf B Biointerfaces 2005, 43(3–4):194-197.
• [2]Wu Q, Rong X, Huang P, Han J, Xu H: Study on inhibitory actions of san huang yi gan capsule (SHYGC) on HBeAg with seropharmacological method. Zhong Yao Cai 2000, 23(5):275-278.
• [3]Zhang YH, Liu JT, Wen BY, Liu N: Mechanisms of inhibiting proliferation of vascular smooth muscle cells by serum of rats treated with Dahuang Zhechong pill. J Ethnopharmacol 2009, 124(1):125-129.
• [4]Zhang H, Xing WW, Li YS, Zhu Z, Wu JZ, Zhang QY, Zhang W, Qin LP: Effects of a traditional Chinese herbal preparation on osteoblasts and osteoclasts. Maturitas 2008, 61(4):334-339.
• [5]Sun J, Bi Y, Guo L, Qi X, Zhang J, Li G, Tian G, Ren F, Li Z: Buyang Huanwu Decoction promotes growth and differentiation of neural progenitor cells: using a serum pharmacological method. J Ethnopharmacol 2007, 113(2):199-203.
• [6]Kao JH: Molecular epidemiology of hepatitis B virus. Korean J Intern Med 2011, 26(3):255-261.
• [7]Perrillo R: Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009, 49(5 Suppl):S103-111.
• [8]Fung J, Lai CL, Seto WK, Yuen MF: Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 2011, 66(12):2715-2725.
• [9]Cox N, Tillmann H: Emerging pipeline drugs for hepatitis B infection. Expert Opin Emerg Drugs 2011, 16(4):713-729.
• [10]Sells MA, Chen ML, Acs G: Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 1987, 84(4):1005-1009.
• [11]Alexander GJ, Fagan EA, Rolando N, Guarner P, Callender ME, Eddleston AL, Williams R: Differential effect of ARA-AMP on serum DNA polymerase activity and serum HBV-DNA in chronic hepatitis B virus infection. A possible reason for lack of efficacy. J Hepatol 1986, 3(Suppl 2):S81-86.
• [12]Samal J, Kandpal M, Vivekanandan P: Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012, 25(1):142-163.
• [13]Tang LL, Sheng JF, Xu CH, Liu KZ: Clinical and experimental effectiveness of Astragali compound in the treatment of chronic viral hepatitis B. J Int Med Res 2009, 37(3):662-667.
• [14]Tseng YP, Wu YC, Leu YL, Yeh SF, Chou CK: Scutellariae radix suppresses hepatitis B virus production in human hepatoma cells. Front Biosci (Elite Ed) 2010, 2:1538-1547.
• [15]Wang S, Li J, Huang H, Gao W, Zhuang C, Li B, Zhou P, Kong D: Anti-hepatitis B virus activities of astragaloside IV isolated from radix Astragali. Biol Pharm Bull 2009, 32(1):132-135.
• [16]Loo WT, Cheung MN, Chow LW: Fructus schisandrae (Wuweizi)-containing compound inhibits secretion of HBsAg and HBeAg in hepatocellular carcinoma cell line. Biomed Pharmacother 2007, 61(9):606-610.
• [17]Li Z, Li LJ, Sun Y, Li J: Identification of natural compounds with anti-hepatitis B virus activity from Rheum palmatum L. ethanol extract. Chemotherapy 2007, 53(5):320-326.
• [18]Kim TG, Kang SY, Jung KK, Kang JH, Lee E, Han HM, Kim SH: Antiviral activities of extracts isolated from Terminalis chebula Retz., Sanguisorba officinalis L., Rubus coreanus Miq. and Rheum palmatum L. against hepatitis B virus. Phytother Res 2001, 15(8):718-720.
• [19]Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ: Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002, 46(8):2525-2532.
• [20]Yamanaka G, Wilson T, Innaimo S, Bisacchi GS, Egli P, Rinehart JK, Zahler R, Colonno RJ: Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999, 43(1):190-193.
• [21]Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ: Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997, 41(7):1444-1448.